Ocular Therapeutix
OCUL
106 hedge funds and large institutions have $321M invested in Ocular Therapeutix in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 9 reducing their positions, and 8 closing their positions.
489% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 9
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
127% more capital invested
Capital invested by funds: $141M → $321M (+$180M)
117% more call options, than puts
Call options by funds: $4.72M | Put options by funds: $2.18M
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
18% more funds holding
Funds holding: 90 → 106 (+16)
7.44% more ownership
Funds ownership: 54.18% → 61.62% (+7.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.01M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.71M |
| 4 |
BlackRock
New York
|
+$5.02M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$5.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.58M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$2.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$161K |
| 4 |
Jane Street
New York
|
-$158K |
| 5 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$111K |
OCUL Hedge Fund Activity: Q2 2020 in Review
106 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2020, worth a combined $321M — up 127% from $141M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new OCUL positions and 8 closed out — a net gain of 16 holders — while 53 added to existing stakes and 9 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $18.1M. The largest seller was Millennium Management, cutting an estimated $6.58M.
- 106 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2020, up from 90 in Q1 2020.
- Funds reported $321M of Ocular Therapeutix stock for Q2 2020, up 127% quarter-over-quarter.
- 24 funds opened new Ocular Therapeutix positions in Q2 2020 and 8 closed out, a net change of +16 holders.
- The largest Ocular Therapeutix buyer in Q2 2020 was RA Capital Management, an estimated $18.1M added.
- The largest Ocular Therapeutix seller in Q2 2020 was Millennium Management, an estimated $6.58M sold.
Based on aggregated 13F filings for Q2 2020.